QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:JNCE

Jounce Therapeutics (JNCE) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$1.88
$1.93
50-Day Range
$1.84
$1.94
52-Week Range
$0.58
$5.87
Volume
11.60 million shs
Average Volume
2.46 million shs
Market Capitalization
$98.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Jounce Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
219.1% Upside
$6.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Balanced
Insiders Both Buying and Selling
Proj. Earnings Growth
Growing
From ($1.71) to ($1.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

300th out of 982 stocks

Biological Products, Except Diagnostic Industry

43rd out of 162 stocks


JNCE stock logo

About Jounce Therapeutics (NASDAQ:JNCE) Stock

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Receive JNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JNCE Stock News Headlines

Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
JNCE Jounce Therapeutics, Inc.
Buyout Offer Sends Jounce Jumping 20%
See More Headlines


JNCE Company Calendar

Last Earnings
11/04/2021
Today
6/07/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:JNCE
Fax
N/A
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+219.1%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-50,920,000.00
Pretax Margin
-61.93%

Debt

Sales & Book Value

Annual Sales
$82 million
Book Value
$3.54 per share

Miscellaneous

Free Float
48,993,000
Market Cap
$98.94 million
Optionable
Optionable
Beta
0.75

Key Executives

  • Kimberlee Cobleigh Drapkin
    President, Chief Financial Officer & Treasurer
  • Eric Laub
    Head-Investor & Media Relations
  • Ted Harding
    Senior Vice President-Human Resources
  • Jacquelyn Fahey Sandell
    Secretary & Chief Legal Officer
  • Allison Nance
    VP-Regulatory Affairs & Quality Assurance













JNCE Stock - Frequently Asked Questions

Should I buy or sell Jounce Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" JNCE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in JNCE, but not buy additional shares or sell existing shares.
View JNCE analyst ratings
or view top-rated stocks.

What is Jounce Therapeutics' stock price forecast for 2023?

4 brokers have issued 12-month target prices for Jounce Therapeutics' shares. Their JNCE share price forecasts range from $3.00 to $11.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 219.1% from the stock's current price.
View analysts price targets for JNCE
or view top-rated stocks among Wall Street analysts.

When is Jounce Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our JNCE earnings forecast
.

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics, Inc. (NASDAQ:JNCE) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.15. During the same period in the previous year, the firm posted ($0.73) earnings per share.

What ETF holds Jounce Therapeutics' stock ?

IQ Merger Arbitrage ETF holds 1,024,423 shares of JNCE stock, representing 0.35% of its portfolio.

What is Richard Murray Ph.D's approval rating as Jounce Therapeutics' CEO?

45 employees have rated Jounce Therapeutics Chief Executive Officer Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among the company's employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jounce Therapeutics own?
When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Who are Jounce Therapeutics' major shareholders?

Jounce Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.84%), JPMorgan Chase & Co. (2.16%), BML Capital Management LLC (2.09%), State Street Corp (1.53%), Geode Capital Management LLC (1.46%) and Beryl Capital Management LLC (1.16%). Insiders that own company stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kevin C Tang, Kimberlee C Drapkin, Richard /Ca/ Murray, Rock Ventures Ii LP Third and Rock Ventures Iii LP Third.
View institutional ownership trends
.

What is Jounce Therapeutics' stock price today?

One share of JNCE stock can currently be purchased for approximately $1.88.

How much money does Jounce Therapeutics make?

Jounce Therapeutics (NASDAQ:JNCE) has a market capitalization of $98.94 million and generates $82 million in revenue each year. The company earns $-50,920,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis.

How many employees does Jounce Therapeutics have?

The company employs 137 workers across the globe.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.jouncetx.com. The company can be reached via phone at (857) 259-3840 or via email at mdeon@jouncetx.com.

This page (NASDAQ:JNCE) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -